• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Sustained Release Ocular Drug Delivery Systems - Product Image

Sustained Release Ocular Drug Delivery Systems

  • ID: 2799925
  • April 2014
  • Region: Global
  • 144 Pages
  • Roots Analysis
Sustained Release Ocular Drug Delivery Systems: What Lies Ahead?

FEATURED COMPANIES

  • Aciont, Inc.
  • Canaan Partners
  • Icon Biosciences
  • Novagali Pharma
  • ProRetina Therapeutics
  • Taiwan Liposome Company
  • MORE

Given the intricacy of the anatomy and physiology of the eye, it is quite challenging to deliver an ophthalmic drug effectively to a specific ocular site.

Several barriers have to be overcome for successful ocular drug delivery. For example, dilution of a drug by tears, clearance of a drug by the lymphatic system of conjunctiva, drug permeation issues with respect to the cornea, sclera, choroid etc. Accordingly, different drug delivery systems have been devised for controlled release of drugs to various parts of the eye.

Intravitreal implants for delivery of drugs to the posterior segment of the eye are already commercially available. Moreover, a number of companies are developing injectable particulate systems for controlled drug delivery to treat such diseases. This has been the primary focus for sustained delivery of drugs till date. However, industry and academia are working on novel implants, including drug-eluting contact lenses and punctal plugs, for treatment of anterior segment diseases such as glaucoma and conjunctivitis.

The ‘Sustained Release Ocular Drug Delivery Systems, 2014 - 2024’ report provides an extensive study of the emerging market READ MORE >

Sustained Release Ocular Drug Delivery Systems: What Lies Ahead?

FEATURED COMPANIES

  • Aciont, Inc.
  • Canaan Partners
  • Icon Biosciences
  • Novagali Pharma
  • ProRetina Therapeutics
  • Taiwan Liposome Company
  • MORE

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Structure of the Eye
3.2. Ocular Drug Delivery Systems
3.2.1. Implantable Ocular Drug Delivery Systems
3.2.1.1. Types of Implants Based on Material
3.2.1.2. Types of Implants Based on Site of Implantation
3.2.2. Particulate Drug Delivery Systems
3.3. Ophthalmic Disorders
3.3.1. Age-related Macular Degeneration (AMD)
3.3.2. Cytomegalovirus (CMV) Retinitis
3.3.3. Diabetic Retinopathy
3.3.4. Diabetic Macular Edema (DME)
3.3.5. Glaucoma
3.3.6. Ocular Infection
3.3.7. Uveitis
3.3.8. Retinal Vein Occlusion

4. Market Overview
4.1. Scope
4.2. Limited Marketed Ocular Systems for Sustained Drug Delivery
4.3. pSivida is the Key Technology Provider
4.4. Pipeline Analysis
4.4.1. Five Systems in Late Stage Development
4.4.2. Nature of Drug Delivery Systems
4.4.3. Novel Implants for Ocular Drug Delivery
4.4.4. Initial Focus on Anti-Inflammatory Drugs
4.4.5. Anterior Eye Diseases: The New Focus
4.4.6. Glaucoma: The Next Big Opportunity?
4.4.7. Universities’ Interest in Ocular Sustained Drug Delivery Systems Market
4.5. Life Cycle Management Tool
4.6. Gene Therapy

5. Product Profiles And Sales Forecast
5.1. Chapter Overview
5.2. Methodology and Assumptions
5.3. Overall Market Size and Forecast
5.4. Vitrasert, Bausch & Lomb, Inc.
5.4.1. Product Overview
5.4.2. Development and Approval History
5.4.3. Product Specifications
5.4.4. Product Advantages
5.4.5. Associated Risks
5.4.6. Price of the Implant
5.4.7. Discontinuation of Vitrasert
5.5. Retisert, Bausch & Lomb, Inc.
5.5.1. Product Overview
5.5.2. Development and Approval History
5.5.3. Product Specifications
5.5.4. Manufacturing of Retisert
5.5.5. Product Advantages
5.5.6. Associated Risks
5.5.7. Price of the Implant
5.5.8. Historical Sales
5.5.9. Sales Forecast
5.6. Iluvien, Alimera Sciences
5.6.1. Product Overview
5.6.2. Development and Approval History
5.6.3. Product Specifications
5.6.4. Manufacturing of Iluvien
5.6.5. Product Advantages
5.6.6. Associated Risks
5.6.7. Price of the Implant
5.6.8. Current Status of Development
5.6.9. Historical Sales
5.6.10. Competition
5.6.11. Opportunity for Iluvien
5.6.12. Sales Forecast
5.7. Ozurdex, Allergan
5.7.1. Product Overview
5.7.2. Development and Approval History
5.7.3. Product Specifications
5.7.4. Associated Risks
5.7.5. Current Status of Development
5.7.6. Historical Sales and Reimbursement
5.7.7. DME to Increase the Market Significantly
5.7.8. Sales Forecast
5.8. OTX-DP, Ocular Therapeutix
5.8.1. Product Specifications
5.8.2. Product Advantages
5.8.3. Current Status of Development
5.8.4. Phase II Clinical Trial Results
5.8.5. Competition
5.8.6. Sales Forecast
5.9. IBI-10090, Icon Biosciences
5.9.1. Product Specifications
5.9.2. Competition
5.9.3. Current Status of Development
5.9.4. Sales Forecast
5.10. DE-102, Santen Pharmaceutical
5.10.1. Product Specifications
5.10.2. Current Status of Development
5.10.3. Sales Forecast
5.11. Medidur, pSivida
5.11.1. Product Specifications
5.11.2. Current Status of Development
5.11.3. Competition
5.11.4. Sales Forecast

6. Company Profiles
6.1. Chapter Overview
6.2. pSivida
6.2.1. Ocular Delivery Technologies
6.2.2. Marketed and Pipeline Products
6.2.3. Financial Performance
6.2.4. Partnerships
6.2.4.1. Pfizer
6.2.4.2. Alimera Sciences
6.2.4.3. Bausch & Lomb
6.2.4.4. Enigma Therapeutics
6.2.4.5. Intrinsiq
6.2.5. Future Plans
6.3. Allergan
6.3.1. Marketed and Pipeline Drugs
6.3.2. Novadur Technology
6.3.3. Financial Performance
6.3.4. Partnerships
6.3.4.1. Oculex Pharmaceuticals
6.3.4.2. Sanwa Kagaku Kenkyusho
6.3.5. Ophthalmic Manufacturing Plant
6.3.6. Future Plans
6.4. Icon Biosciences
6.4.1. Verisome Technology
6.4.2. Advantages
6.4.3. Pipeline Products
6.4.4. Funding
6.4.5. Future Plans
6.5. Santen Pharmaceutical
6.5.1. Ophthalmology: Leading Marketed Drugs
6.5.2. Pipeline Products
6.5.3. CHRONIJECT Microsphere Technology
6.5.4. Partnerships
6.5.4.1. Oakwood Laboratories
6.5.4.2. Novagali Pharma
6.5.5. Manufacturing Facilities
6.5.6. Financial Performance
6.6. Neurotech Pharmaceuticals
6.6.1. Encapsulated Cell Technology
6.6.2. Pipeline Products
6.6.2.1. Evolution of NT-503
6.6.2.2. Development of NT-501
6.6.3. Funding
6.6.4. ECT Manufacturing Facility
6.6.5. Future Plans
6.7. Ocular Therapeutix
6.7.1. Hydrogel Technology
6.7.2. Marketed and Pipeline Products
6.7.3. Funding
6.7.4. Future Plans

7. SWOT Analysis
7.1. Chapter Overview
7.2. Strengths
7.3. Weaknesses
7.4. Opportunities
7.5. Threats

8. Interview Transcripts
8.1. Interview 1: Mati Therapeutics, Bob Butchofsky, Founder and CEO
8.2. Interview 2: On Demand Therapeutics, John Santini, President and CEO
8.3. Other Anonymous Respondents

9. Conclusion
9.1. Commercial Implants Are Limited; Current Adoption is Low
9.2. Ophthalmic Indications: Short and Long Term Drivers for Market Growth
9.3. Emerging Technologies
9.4. Opportunities Outweigh the Challenges
9.5. A Billion Dollar Market within a Decade

10. Appendix 1: Tabulated Data

11. Appendix 2: List of Companies and Organizations

List of Figures

Figure 4.1 Ocular Drug Delivery Implants: Approval Timeline
Figure 4.2 Sustained Release Ocular Drug Delivery Systems: Split by Phase of Development
Figure 4.3 Sustained Release Ocular Drug Delivery System: Split by Nature of System
Figure 4.4 Sustained Release Ocular Drug Delivery Systems: Split by Target Indication
Figure 4.5 Sustained Release Ocular Drug Delivery Systems, University Research: Split by Target Indication
Figure 4.6 Lucentis Sales (USD million), 2010-2013
Figure 5.1 Overall Sales Forecast, 2014 - 2024, USD Million (Base Scenario)
Figure 5.2 Retisert Sales (USD million), 2010 - 2012
Figure 5.3 Retisert Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.4 Retisert Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.5 Iluvien Sales (USD), Q2 - Q4 2013
Figure 5.6 IVT Treated DME: US Market Share by Leading Drugs (%)
Figure 5.7 Iluvien Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.8 Iluvien Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.9 Ozurdex Development Timeline
Figure 5.10 Ozurdex Sales (USD million), 2010 – 2012
Figure 5.11 Ozurdex Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.12 Ozurdex Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.13 OTX-DP Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.14 OTX-DP Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.15 IBI-10090 Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.16 IBI-10090 Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.17 DE-102 Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.18 DE-102 Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.19 Retisert, Ozurdex and Iluvien: Percentage Share of Patients Reported to Have Developed IOP
Figure 5.20 Medidur Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.21 Medidur Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 6.1 pSivida Revenues (USD ‘000) - 2011, 2012 and 2013
Figure 6.2 Allergan: Sales for Leading Marketed Ophthalmic Drugs (USD Million), 2012
Figure 6.3 Allergan: Revenue by Business Segment, 2013 (USD Million)
Figure 6.4 Allergan Specialty Pharmaceuticals Revenues, 2013 (USD Million)
Figure 6.5 Icon Biosciences Milestone Chart
Figure 6.6 Santen: Sales of Leading Marketed Ophthalmology Drugs (JPY Million), 2013 and 2012
Figure 6.7 Santen: Revenues by Segment, 2013 (JPY Million)
Figure 6.8 Santen Pharmaceutical: Revenue by Sub-Segments (JPY Million), 2013
Figure 6.9 Neurotech Pharmaceuticals: Timeline
Figure 9.1 Sustained Release Ocular Drug Delivery Systems Market, 2014, 2019, 2024 (USD Million)

List of Tables

Table 3.1 Eye: Description of Tissue Layers
Table 4.1 Availability of Ocular Drug Delivery Implants in the US and Europe
Table 4.2 Sustained Release Ocular Drug Delivery Systems: Pipeline
Table 4.3 Sustained Release Ocular drug delivery system: Research Projects at Universities
Table 4.4 Gene Therapies under Development for Ocular Diseases
Table 5.1 Current Development Phase and Expected Launch Year of Drug Delivery Systems (Phase III and Higher)
Table 5.2 Iluvien: Status of Development
Table 5.3 Comparison of Iluvien with Currently Available Drugs for DME
Table 5.4 Vision Loss Associated with DME, Number of Patients in the US and Major EU Countries, 2012
Table 5.5 Market Potential for Iluvien in the US
Table 5.6 Approval of Ozurdex in different Geographies
Table 5.7 Ozurdex: Current Status of Development
Table 5.8 OTX-DP: Ongoing Clinical Trials
Table 5.9 IBI10090: Competitive Landscape
Table 5.10 IBI-10090 and Marketed Topicals: Comparison of Anterior Chamber Cell Count
Table 5.11 IBI-10090: Current Status of Development
Table 5.12 DE-102: Ongoing Clinical Trials
Table 5.13 Medidur: Status of Development
Table 5.14 Medidur: Competitive Landscape
Table 5.15 Medidur and Available Drugs for Posterior Uveitis: Comparative Analysis
Table 6.1 pSivida: Marketed and Pipeline Ocular Delivery Systems
Table 6.2 Allergan: Marketed and Pipeline Sustained Release Ocular Drug Delivery System
Table 6.3 Icon Biosciences: Clinical Pipeline
Table 6.4 Santen: Pipeline of Ophthalmology Drugs
Table 6.5 Neurotech Pharmaceuticals: Pipeline of Products
Table 6.6 NT-501: Orphan Drug and Fast Track Designations
Table 6.7 Ocular Therapeutix: Marketed and Pipeline Products
Table 7.1 Sustained Release Ocular Drug Delivery Systems: SWOT Analysis
Table 7.2 Development of Sustained Release Ocular Systems: Venture Capital Funding
Table 10.1 Sustained Release Ocular Drug Delivery Systems: Split by Phase of Development
Table 10.2 Sustained Release Ocular Drug Delivery Systems: Split by Nature of System
Table 10.3 Sustained Release Ocular Drug Delivery Systems: Split by Target Indication
Table 10.4 Sustained Release Ocular Drug Delivery Systems, University Research: Split by Target Indication
Table 10.5 Overall Sales Forecast, 2014 - 2024, USD Million (Base Scenario)
Table 10.6 Overall Sales Forecast, 2014 - 2024, USD Million (Conservative Scenario)
Table 10.7 Overall Sales Forecast, 2014 - 2024, USD Million (Optimistic Scenario)
Table 10.8 Retisert Sales Forecast, 2014 - 2024, USD Million (Base Scenario)
Table 10.9 Retisert Sales Forecast, 2014 - 2024, USD Million (Conservative Scenario)
Table 10.10 Retisert Sales Forecast, 2014 - 2024, USD Million (Optimistic Scenario)
Table 10.11 IVT Treated DME: US Market Share by Leading Drugs (%)
Table 10.12 Iluvien Sales Forecast, 2014 - 2024, USD Million (Base Scenario)
Table 10.13 Iluvien Sales Forecast, 2014 - 2024, USD Million (Conservative Scenario)
Table 10.14 Iluvien Sales Forecast, 2014 - 2024, USD Million (Optimistic Scenario)
Table 10.15 Ozurdex Sales Forecast, 2014 - 2024, USD Million (Base Scenario)
Table 10.16 Ozurdex Sales Forecast, 2014 - 2024, USD Million (Conservative Scenario)
Table 10.17 Ozurdex Sales Forecast, 2014 - 2024, USD Million (Optimistic Scenario)
Table 10.18 OTX-DP Sales Forecast, 2014 - 2024, USD Million (Base Scenario)
Table 10.19 OTX-DP Sales Forecast, 2014 - 2024, USD Million (Conservative Scenario)
Table 10.20 OTX-DP Sales Forecast, 2014 - 2024, USD Million (Optimistic Scenario)
Table 10.21 IBI-10090 Sales Forecast, 2014 - 2024, USD Million (Base Scenario)
Table 10.22 IBI-10090 Sales Forecast, 2014 - 2024, USD Million (Conservative Scenario)
Table 10.23 IBI-10090 Sales Forecast, 2014 - 2024, USD Million (Optimistic Scenario)
Table 10.24 DE-102 Sales Forecast, 2014 - 2024, USD Million (Base Scenario)
Table 10.25 DE-102 Sales Forecast, 2014 - 2024, USD Million (Conservative Scenario)
Table 10.26 DE-102 Sales Forecast, 2014 - 2024, USD Million (Optimistic Scenario)
Table 10.27 Medidur Sales Forecast, 2014 - 2024, USD Million (Base Scenario)
Table 10.28 Medidur Sales Forecast, 2014 - 2024, USD Million (Conservative Scenario)
Table 10.29 Medidur Sales Forecast, 2014 - 2024, USD Million (Optimistic Scenario)
Table 10.30 pSivida Revenues (USD ‘000) - 2011, 2012 and 2013
Table 10.31 Allergan: Revenue by Business Segment (USD Million), 2012 and 2013
Table 10.32 Allergan Specialty Pharmaceuticals Revenues (USD Million), 2013
Table 10.33 Santen: Sales of Leading Marketed Ophthalmology Drugs (JPY Million), 2013 and 2012
Table 10.34 Santen: Revenues by Segment (JPY million), 2012 and 2013
Table 10.35 Santen Pharmaceutical: Revenue by Sub-Segments (JPY million), 2013

Sustained Release Ocular Drug Delivery Systems: What Lies Ahead?

FEATURED COMPANIES

  • Aciont, Inc.
  • Canaan Partners
  • Icon Biosciences
  • Novagali Pharma
  • ProRetina Therapeutics
  • Taiwan Liposome Company
  • MORE

Sample Highlights

- Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien.

- Out of 42 sustained release ocular drug delivery systems (marketed / under development), 3 are already marketed for specific indications and 14 are in Phase II or Phase III of development.

- Diabetic Macular Edema (DME) will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. The potential in the market is huge with a high target population, which is growing significantly due to the rise in cases of diabetes.

- In the mid to long term, the growth will be boosted by launch of sustained release systems for glaucoma and AMD. At least three companies have sustained release systems delivering prostaglandin analogues in phase II development and one in phase I/II for the treatment of glaucoma and ocular hypertension.

- The overall market is likely to be more than USD 1 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics.

Sustained Release Ocular Drug Delivery Systems: What Lies Ahead?

- Aciont, Inc.
- Alimera Sciences
- Allergan
- Alliance Medical products Inc.
- Amorphex Therapeutics
- Apax Partners
- Applied Genetic Technologies Corporation
- Ascension Health Ventures
- Auritec Pharmaceuticals
- Avalanche Biotech
- Bausch & Lomb
- Baxter Ventures
- Ben Venue Laboratories
- Biolight Israeli Life Sciences Investments Ltd.
- Brandon Capital
- Brecon Pharmaceuticals Ltd
- Burrill and Company
- Canaan Partners
- Ceregene
- Duke University Medical Center
- Enigma Therapeutics
- Envisia Therapeutics
- EOS Neuroscience
- Euclid Systems Corporation
- EVS Glaucoma Therapeutics
- FARMABIOS SpA / Byron Chemical Company
- FDA
- Flextronics International Ltd
- ForSight VISION 4
- Genable Technologies
- Genentech
- Genzyme
- Graybug
- Hemera Biosciences
- Hospital Research Center, Linkoping University,
- Icon Biosciences
- IIT Roorkee
- Intrinsiq
- Johns Hopkins University
- Kyoto University, Faculty of Medicine
- Lonza
- Lux Biosciences
- Maryland Venture Fund
- Mati Therapeutics
- Medical Research Commercialisation Fund (MRCF)
- Merlin Biosciences
- MIT, Boston
- Morningside Technology Ventures
- National Eye Institute
- National Tsing Hua University
- Neurotech Pharmaceuticals
- New Enterprise Associates
- Nishi Eye Hospital, Osaka, Japan
- Novagali Pharma
- Novartis
- NTU, Singapore
- Oakwood Laboratories
- OctoPlus
- Ocular Therapeutix
- Oculex Pharmaceuticals
- On Demand Therapeutics
- Oxford Biomedica
- Pappas Ventures
- Pfizer
- Polaris Venture Partners
- Polyactiva
- ProRetina Therapeutics
- pSivida
- QLT
- ReGenX Biosciences
- Replenish Inc
- RetroSense Therapeutics
- Roche
- Sanofi Aventis
- Santen
- Sanwa Kagaku Kenkyusho
- Sao Paulo State University
- School of Pharmacy, West Virginia University, USA
- Signet Healthcare Partners
- Singapore Eye Research Institute
- Sparta LLC
- Specialty Pharmaceuticals
- SV Life Sciences
- Taiwan Liposome Company
- Tulane University Medical Center
- United Centers for Advanced Research and Translational Medicine (ART)
- University of California
- University of Colorado
- University of Florida
- University of Miami
- University of Nebraska
- University of Ottawa, Ottawa
- University of Pittsburgh
- University of Southern California
- University of Waterloo, Canada
- Valeant Ophthalmics
- Versant Ventures
- Wakefield Group
- Wayne State University
- Wellstat Ophthalmics
- Yuuwa Capital

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos